Researchers have identified that α-synuclein plays a role in DNA repair in neurons and that disruption of this function could lead to widespread death of neurons.
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
MRI scans of individuals living with multiple sclerosis could predict how the disease will progress in the following years. This information could potentially be useful when considering treatment options.
New research suggests that exosomes could play an important role in brain circuits, cell signaling and cell communication.
Looking at your phone in the middle of the night won’t affect your body’s overall circadian rhythm, researchers suggest, as short-term and long-term exposure to light is processed via different pathways.
This week in industry we’re taking a look at the discontinuation of umibecestat and Acthar® Gel for Alzheimer’s and ALS, respectively, as well as the drug discovery shift from the amyloid approach in the Alzheimer’s field.
New studies presented at AAIC 2019 reveal that sex-specific differences could play a role in the risk, progression and resilience of Alzheimer’s disease.
Studies presented at AAIC 2019 have revealed the significant advances being made in the global search for blood-based biomarkers for dementia.
Observational studies reveal that use of sleep medications can increase an individual’s chances of developing dementia in sex-specific and race-specific ways.
Studies presented at AAIC 2019 provide potential treatment methods for the improvement of sleep quality in individuals with dementia.